GSA Capital Partners LLP lowered its stake in shares of Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) by 36.8% during the third quarter, according to the company in its most recent disclosure with ...

Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So, the natural question for Biomea Fusion (NASDAQ:BMEA) ...

Biomea Fusion, Inc. (NASDAQ:BMEA – Get Free Report) has been given an average recommendation of “Buy” by the twelve analysts that are covering the firm, MarketBeat Ratings reports.

On Thursday, Biomea Fusion Inc (BMEA) stock saw a decline, ending the day at $9.37 which represents a decrease of $-0.97 or -9.38% from the prior close of $10.34. The stock opened at $10.46 and ...

Zeit Aktuelle Nachrichten 05.11. Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook 01.11. Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635 ...

REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical ...

REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and ...

REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery ...

On Thursday, Piper Sandler adjusted its outlook on Biomea Fusion Inc. (NASDAQ:BMEA), increasing the price target to $19.00, up from the previous $10.00, while maintaining an Overweight rating on the ...